Skip to main content
. 2015 Feb 9;125(3):1228–1242. doi: 10.1172/JCI77656

Figure 3. Disruption of EP3 ameliorates PAH and pulmonary vascular remodeling in HySu-induced PAH in mice.

Figure 3

(A) RVSP in Ep3–/– and WT mice after HySu treatment. (B) RV/LV+S in Ep3–/– and WT mice after HySu treatment. (C) Representative images of H&E staining and α-SMA (green) immunostaining of lung sections from HySu-treated Ep3–/– and WT mice. Scale bar: 20 μm. (D) Quantification of the ratio of vascular medial thickness to total vessel size for the HySu treatment model. (E) Proportion of non-, partially, or full muscularized pulmonary arterioles (20–50 μm in diameter) from HySu-treated mice. (A–E) n = 7 mice. *P < 0.05 versus WT and #P < 0.05 versus control by 2-way ANOVA with Bonferroni’s post-hoc analysis.